Skip to main content
SpringerLink
Log in

Using drug utilisation review to assess the appropriateness of thrombolytic therapy

  • Drug Economics and Quality of Life
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. McGlynn S. Criteria for drug usage review of thrombolytics in acute myocardial infarction. PharmacoEconomics 1995; 7: 25–38

    Article  PubMed  CAS  Google Scholar 

  2. GISSI (Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardio). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1988; 1: 397–401

    Google Scholar 

  3. ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349–59

    Google Scholar 

  4. Wilcox RG, Olsson CG, Skene AM, et al. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Lancet 1988; 2: 525–30

    Article  PubMed  CAS  Google Scholar 

  5. AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancet 1988; 1: 545–9

    Google Scholar 

  6. Blackburn JL. Impact of drug usage review on drug utilisation. PharmacoEconomics 1993; 3: 14–21

    Article  PubMed  CAS  Google Scholar 

  7. Stolar MH. Drug use review: operational definitions. Am J Hosp Pharm 1978; 35: 76–8

    PubMed  CAS  Google Scholar 

  8. Sacristán JA, Soto J. Drug utilisation studies as tools in health economics. PharmacoEconomics 1994; 5: 299–312

    Article  PubMed  Google Scholar 

  9. ASHP guidelines on the pharmacist’s role in drug use evaluation. Am J Hosp Pharm 1988; 45: 385–6

    Google Scholar 

  10. Fibrinolytic Therapy Trialist (FIT) Collaborative Group. Indications for fibrinolytic therapy in suspected myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311–21

    Google Scholar 

  11. Rubin RN. Choosing a thrombolytic agent in acute MI. Drug Ther 1992; 22: 17–32

    Google Scholar 

  12. Figueredo VM, Amidon TM, Wolfe CL. Thrombolysis after acute myocardial infarction. Postgrad Med 1994; 96: 30–40

    PubMed  CAS  Google Scholar 

  13. Fendrick AM, Ridker PM, Bloom BS. Improved health benefits of increased use of thrombolytic therapy. Arch Intern Med 1994; 154: 1605–9

    Article  PubMed  CAS  Google Scholar 

  14. Ketley D, Woods KL. Impact of clinical trials on clinical practice: example of thrombolysis for acute myocardial infarction. Lancet 1993; 342: 891–4

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Using drug utilisation review to assess the appropriateness of thrombolytic therapy. Drugs Ther. Perspect 5, 14–16 (1995). https://doi.org/10.2165/00042310-199505080-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199505080-00006

Keywords

Search

Navigation